一品紅(300723.SZ):擬通過瑞奧生物對華南疫苗增資4988.07萬元
格隆匯3月17日丨一品紅(300723.SZ)公佈,公司間接控股子公司華南疫苗是一家專注於重組蛋白納米顆粒疫苗研發的創新生物醫藥企業。因前期研發工作進展及後續業務持續推進,需要加大研發投入並儲備發展資金。公司擬通過子公司瑞奧生物以自有資金4988.07萬元人民幣對華南疫苗進行增資,其中417.97萬元計入華南疫苗註冊資本,其餘部分計入標的公司資本公積金。其餘份額由其他投資人認購。
本次增資完成後,華南疫苗的註冊資本由2735.04萬元增至3154.01萬元,公司持股比例將由52.7077%提升至58.9582%,仍為華南疫苗控股股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.